The US Food and Drug Administration (FDA) will evaluate seven peptides in July to determine if they should be added to a list of substances that can be safely produced by compounding pharmacies.
In 2025, the FDA placed several peptides into a limited category, stating they should not be used in compounded drugs due to potential risks. Soon, the FDA will remove these peptides from the list. This follows US Health and Human Services Secretary Robert F. Kennedy Jr.’s push to deregulate peptides, according to media reports.
FDA experts will first evaluate:
· BPC-157: used for tissue repair and to cool inflammation
· KPV: used to cool inflammation and boost wound healing
· TB-500 (Thymosin-4): used for injury recovery
· MOTs-C: studied for obesity and osteoporosis
· Emideltide (DSIP): used for insomnia and opioid withdrawal
· Semax: explored for neurological issues
· Epitalon: used for insomnia
Next up, another FDA panel will review five peptides by February 2027, including:
Cathelicidin (LL-37) GHK-Cu Dihexa acetate Melanotan II Mechano Growth Factor, Pegylated (PEG-MGF)